Additional data about safety.

Additional data about safety, tolerability of Cempra’s solithromycin to be presented at 51st ICAAC Today announced abstracts to be presented on its 4th generation macrolide and novel fluoroketolide antibiotic Cempra Pharmaceuticals, solithromycin , at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy , 17 to 20 September, 2011, in Chicago. The compound has potent in vitro activity against respiratory pathogens such as for example pneumococci, including macrolide – and quinolone-resistant strains. CEM-101 provides completed Stage 2 trials in community-obtained bacterial pneumonia for the oral dosage type and is in Phase 1 for the IV dosage type sulbutiamine reddit .